Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #715 on Abbvie Inc (ABBV)
DewDiligence
06/15/23 3:46 PM
#737 RE: DewDiligence #715
Because of Imbruvica’s toxicity [see #msg-170086344], the National Comprehensive Cancer Network (NCCN) recently downgraded its guidance on Imbruvica, removing the AbbVie/J&J drug from a “preferred” regimen status. The NCCN guidelines committee has instead placed [BGNE’s] Brukinsa above Imbruvica in several areas. …Facing double pressure from Brukinsa and AstraZeneca’s Calquence, Imbruvica has been on fast decline. First-quarter sales of the first-generation BTK inhibitor dropped 25% year on year to $878 million for AbbVie.